-
The annual output value can reach 10 billion yuan!
Time of Update: 2022-02-22
After the project is completed, the annual output value will reach 10 billion yuan, which will speed up the company's new drug industrialization process, and will also help boost the development of Yantai's biopharmaceutical industry .
-
Recently, Lilly has reached a number of cooperation, and has laid out a number of market targets exceeding 100 billion
Time of Update: 2022-02-22
If Eli Lilly is responsible for clinical development and commercialization, Heyu Pharma has the right to receive potential fees of up to $258 million based on the results of predetermined preclinical, clinical development and commercial milestones, as well as sales tiered royalties arising from the agreement fee .
-
In the next 5-10 years, domestic centrifuges are expected to enter a new stage of high-quality development
Time of Update: 2022-02-22
In recent years, Lu Xiangyi has also exported products to many countries in the world while ensuring the supply of domestic centrifuge products, and has increased investment in some high-tech products through technical exchanges and cooperation with many overseas enterprises.
-
With over 150 projects under development and more than 60 reviewed products in hand, this pharmaceutical company is at full capacity!
Time of Update: 2022-02-22
As a second-generation EGFR-positive lung cancer targeted drug, it was officially approved for marketing in China in 2019, and has been included in the new version of the National Drug List.
-
This week, a group of pharmaceutical companies spent huge sums of money to launch large-scale mergers and acquisitions!
Time of Update: 2022-02-21
Cosette is a manufacturer of dermatological products with high-quality production facilities for the manufacture of various pharmaceutical dosage forms such as suppositories, creams, ointments, liquids and gels, and is active in the field of dermatology and the treatment of allergic diseases R&D pipeline .
-
Within 1 day, the pharmaceutical company issued 9 announcements in a row!
Time of Update: 2022-02-21
ZHU ZHENPING, the company's director/deputy general manager/R&D leader/core technician, applied to resign from the fourth session of the company's board of directors due to work adjustment.
ZHU ZHENPING joined Sunshine Guojian as director, deputy general manager, head of R&D, and core technical staff of the company .
-
The pharmaceutical company officially disclosed its annual report!
Time of Update: 2022-02-21
According to the annual report, in 2021, Wohua Pharmaceutical achieved operating income of 943 million yuan, a year-on-year decrease of 6.
39% compared with the same period of last year, and the sales revenue of Hedan tablets/capsules decreased by 22.
-
Committed to producing more reliable clean products to help the progress and development of health care
Time of Update: 2022-02-17
In response to the excessive use of plastics in the storage process of major dairy brands, Kinglai has developed a new type of residue-free clean powder box (hereinafter referred to as the powder box) to ensure safety and environmental protection for the last storage process of milk powder before canning .
-
The two pharmaceutical companies announced their "breakup" after less than a year of cooperation!
Time of Update: 2022-01-27
It is worth noting that Junshi Bio has also disclosed an announcement recently that it has decided to terminate the promotion cooperation with AstraZeneca and withdraw the promotion rights of toripalimab injection agreed in the original agreement .
-
$124 million!
Time of Update: 2022-01-27
Specifically, the agreement shows that Shufang Pharmaceutical has obtained the exclusive right to develop and commercialize Vamorolone in Greater China for Duchenne muscular dystrophy and other rare disease indications .
-
$174 million!
Time of Update: 2022-01-27
. On November 19, 2021, Renfu Medicine announced that it had signed a "Share Transfer Agreement" with Anda North America, and planned to transfer 2.
-
Pharmaron acquired large production bases and continued to deploy CDMO tracks
Time of Update: 2022-01-26
Recently, domestic CDMO giant Pharmaron announced that it has successfully acquired Aesica Pharmaceuticals, a subsidiary of Recipharm in Cramlington, UK, aiming to further enhance the overall strength of the small molecule CDMO service platform .
-
Only one week after the start of the New Year, this pharmaceutical company has obtained 288 institutions to get together for research
Time of Update: 2022-01-26
In terms of the product layout of industrial microorganisms in various sub-fields, Huadong Medicine said that the company's industrial microorganism business can be divided into four categories: pharmaceutical raw materials and high-end intermediates, special functional chemicals, large health and medical beauty raw materials, biological materials and enzyme preparations.
-
This pharmaceutical company will use 717 million to develop innovative drugs!
Time of Update: 2022-01-26
Regarding the purpose of transferring part of the equity of Tebao Bio, Tonghua Dongbao stated that it is mainly to withdraw funds, concentrate its efforts on the development of innovative pharmaceutical companies, and provide financial support for Tonghua Dongbao to deploy innovative drugs .
-
Aiming at the $100 billion oncology drug market, this pharmaceutical company "has another city"
Time of Update: 2022-01-25
For the blockbuster antibody drugs in the commercialization stage introduced by this cooperation, Sinovac said that it will help Sinovac to expand its product pipeline, further improve the company's overseas market layout, and provide treatment options for unmet clinical needs .
-
In order to expand production capacity and optimize production processes, the pharmaceutical company plans to invest 150 million overseas
Time of Update: 2022-01-24
On January 12, Jiudian Pharmaceutical announced that it plans to invest 157 million yuan to build the construction project (Phase I) of Jiudian Pharmaceutical's high-end formulation research and development industrial park on Jiankang Avenue in Liuyang Economic Development Zone .
-
A pharmaceutical company with a market value of 100 billion US dollars has reported layoffs!
Time of Update: 2022-01-23
In fact, in recent years, under the background of accelerating changes in the pharmaceutical landscape, layoffs, personnel changes, and business adjustments seem to have become normal actions for both multinational and local pharmaceutical companies .
-
At the beginning of the new year, good news for a pharmaceutical company's new drug research and development continues
Time of Update: 2022-01-23
According to reports, at the beginning of the year, Yichang Renfu Pharmaceutical's Class 2 new drug injection RF16001 received the "Clinical Trial Approval Notice" issued by the State Drug Administration.
In recent years, Renfu Medicine has continuously increased its R&D investment.
-
Pfizer reached a number of cooperation within two days to further promote the development of anti-cancer drugs
Time of Update: 2022-01-23
. On January 11, PostEra, a biotechnology company focusing on machine learning in the field of preclinical drug development, announced that it has expanded its existing strategic cooperation with Pfizer .
-
Within two days, a pharmaceutical company spent huge sums of money to introduce a number of new technologies one after another.
Time of Update: 2022-01-23
Under the agreement, Pfizer paid Dren Bio an upfront payment of $25 million, while the company is also eligible to receive development, regulatory and commercialization milestone payments totaling more than $1 billion .
